Pharma Marketing News Vol. 9, #10: DECEMBER 2010

Welcome to the DECEMBER 2010 issue of Pharma Marketing News. This is the Executive Summary. This executive summary includes links to ALL the DECEMBER 2010 articles.

Pharma Marketing News Vol. 9, #9: NOVEMBER 2010

Welcome to the NOVEMBER 2010 issue of Pharma Marketing News. This is the Executive Summary. This executive summary includes links to ALL the NOVEMBER 2010 articles.

Real Patient Testimonials

This article discusses the potential pitfalls, regulatory issues, and best practices regarding the use of real patient testimonials based on comments collected from a recent survey of readers and other experts.

Capturing & Reporting HCP-Related Meeting Spending

Life Science companies are struggling to understand the complex reporting requirements and compliance issues presented by existing and new regulations like the Sunshine Act. This article is a summary of a Webinar by StarCite, which defined what pharma marketers and meeting planners need to know when it comes to meetings-related HCP reporting.

Pharma Marketing News Vol. 9, #5: May 2010

Welcome to the MAY 2010 issue of Pharma Marketing News.

Pfizer’s SamplesDirect eSampling Program

Pfizer has become the latest drug company to offer doctors the option of using the Internet to order free samples of its drugs, a trend illustrating the diminished role of sales representatives, whose ranks continue to decrease. The service is called SamplesDirect.

Ad Execs Not Viewed as Innovative By Americans Says AstraZeneca Survey

Sorry to break this to you, but Americans don't think advertising executives are very innovative. The AZ survey shows that Americans think advertising executives are only as innovative as teachers, but much less innovative than doctors, artists, engineers, or scientists.

Pharma Marketing News Vol. 9, #3: March 2010

Welcome to the MARCH 2010 issue of Pharma Marketing News.

Pharma Marketing News Vol. 9, #4: April 2010

Welcome to the APRIL 2010 issue of Pharma Marketing News.

Overcoming Space Limitations in Social Media

This article presents a summary of comments to FDA from the drug industry addressing regulatory concerns when using social media tools associated with space limitations or tools that allow for real-time communications to present product information.

STAY CONNECTED

30,126FollowersFollow
- Advertisement -